Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy over the past decade. The indications for the...

Full description

Saved in:

Bibliographic Details
Published in:	Nature reviews. Clinical oncology Vol. 16; no. 9; pp. 563 - 580
Main Authors:	Martins, Filipe, Sofiya, Latifyan, Sykiotis, Gerasimos P, Lamine, Faiza, Maillard, Michel, Fraga, Montserrat, Shabafrouz, Keyvan, Ribi, Camillo, Cairoli, Anne, Guex-Crosier, Yan, Kuntzer, Thierry, Michielin, Olivier, Peters, Solange, Coukos, Georges, Spertini, Francois, Thompson, John A, Obeid, Michel
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.09.2019
Subjects:	Adverse events Antineoplastic Agents, Immunological - adverse effects Apoptosis Biopsy Cancer therapies Cell death Chemotherapy CTLA-4 protein Cytotoxicity Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - therapy Epidemiology Humans Immune checkpoint inhibitors Immunologic Factors - adverse effects Immunotherapy - adverse effects Immunotherapy - methods Inflammation Lymphocytes T Malignancy Management Neoplasms - drug therapy Oncology Patients PD-1 protein PD-L1 protein Risk factors Risk groups Side effects Surveillance
ISSN:	1759-4774, 1759-4782, 1759-4782
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!